CN103048453A - Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof - Google Patents
Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof Download PDFInfo
- Publication number
- CN103048453A CN103048453A CN2012105501708A CN201210550170A CN103048453A CN 103048453 A CN103048453 A CN 103048453A CN 2012105501708 A CN2012105501708 A CN 2012105501708A CN 201210550170 A CN201210550170 A CN 201210550170A CN 103048453 A CN103048453 A CN 103048453A
- Authority
- CN
- China
- Prior art keywords
- antibody
- related antigen
- reagent
- carbohydrate related
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to a nanometer magnetic particle chemiluminescence detection kit for a carbohydrate antigen CA19-9 as well as a preparation method thereof and a detecting method thereof. The kit comprises a solution, which contains a fluorescein labeled carbohydrate related antigen CA19-9, a suspension, which is coated with a fluorescein antibody, and a solution, which contains an alkaline phosphatase labeled carbohydrate related antigen CA19-9 antibody, wherein the alkaline phosphatase labeled carbohydrate related antigen CA19-9 antibody is obtained by connecting an alkaline phosphatase and the carbohydrate related antigen CA19-9 antibody through cross-linking agents SMCC and 2-IT. According to the invention, the carbohydrate related antigen CA19-9 can be quantitatively detected with lower cost, higher accuracy and higher precision.
Description
Technical field
The invention belongs to biological technical field, be specifically related to nano magnetic particulate chemistry luminescence assays kit and preparation method thereof and the detection method of a kind of carbohydrate related antigen CA19-9 that combines immune magnetic particle isolation technics and chemiluminescence immunoassay technology.
Background technology
Sugar antigen CA19-9(Carbohydrate Antigen19-9) be glycolipid matter on the cell membrane, molecular weight is about 1000KD.CA19-9 be 1979 by the colon cancer cell immune mouse such as Koprowski, and with myeloma hybridization gained 116NS19-9 monoclonal antibody and name, be hitherto reported to the highest mark of cancer of pancreas susceptibility.
CA19-9 is mainly used in following aspect clinically:
Malignant tumor of digestive tract
Cancer of pancreas, liver and gall are that the CA 19-9 level of cancer, cancer of the stomach, colorectal cancer is respectively 683,535,279,115 times of normal mean value.And positive rate with cancer of pancreas for the highest, indicate preferably therefore CA19-9 is cancer of pancreas.
Application in the diagnosis of pancreatic cancer:
Most of Pancreas cancer patients serum CA 19-9 levels obviously increases.If take the normal reference range upper limit (37U/mL) as diagnostic criteria, susceptibility and specificity all can reach more than 90%; The CA19-9 level is relevant with the stage of tumour, the complexity of the height of content prompting operation in the serum; The CA19-9 level has certain suggesting effect to prognosis before the art, and low person's prognosis is better; Postoperative CA19-9 level is down to normal person and is longer than not descender life cycle; During tumor recurrence, CA19-9 can raise once again, and betides before the imaging diagnosis.Therefore can be used as the recurrence of monitoring tumour.
Other malignant tumours
The positive rate of oophoroma, lymthoma, cancer of the stomach, liver cancer, the cancer of the esophagus, breast cancer is lower.Use as follows:
The positive rate of cancer of the stomach is about 25%-60%, and relevant with neoplasm staging.For patients with gastric cancer, detect simultaneously CEA and can improve positive rate; Rectum, colorectal cancer patients, positive rate are 18%-58%, and be relevant with neoplasm staging.Measure simultaneously CEA and can improve susceptibility, if treatment effectively, the CA19-9 decline rate is fast than CEA; The CA19-9 positive rate of carcinoma of gallbladder, cholangiocarcinoma, cancer of bile ducts is higher, can be used for distinguishing jaundice and the obstructive jaundice of cancer of pancreas, cholangiocarcinoma merging.The latter's CA19-9 level is lower.
Using priciple: CA19-9 and AFP, CEA joint inspection help to improve the diagnosis efficiency of gastroenteric tumor.
Non-neoplastic disease
Low concentration increases, one cross property and increase and be found in chronic pancreatitis, cholelithiasis, cirrhosis, renal insufficiency, diabetes etc.
Immune analysis method for detection of sugar antigen CA19-9 mainly contains enzyme-linked immunosorbent assay, chemiluminescence immunoassay etc. at present.The methodology limiting factors such as enzyme-linked immunosorbent assay exists sensitivity low, and narrow, the difficult realization of the range of linearity is full-automatic.Chemiluminescence immunoassay is a kind of immunoassay technology that grows up on the enzyme-linked immunosorbent assay basis, have highly sensitive, detect the advantages such as linear wide ranges, easy and simple to handle, automaticity height.At present chemiluminescence immunoassay technology has above-mentioned manyly be widely used a little because of it.
Yet, in the immune detection of reality, owing to impurity component contained in the testing sample is more, detection sensitivity and accuracy have been affected to a certain extent, so from the sample substrate of complexity, separate fast, be purified into the purpose determinand, it is one of difficult problem of facing of clinical examination worker.
The magnetic particle immunoassay technology is to utilize the magnetic solid phase particle of synthesis of polymer material certain particle size size to make carrier, have the various immunologic active materials such as the antibody of specificity affinity or antigen on coated with methods such as physisorption, chemical couplings, have that velocity of separation is fast, efficient is high, the characteristics such as favorable repeatability, simple to operate, the biological character that do not affect separated cell or other biological material and function, adding orientable motion under the magnetic fields, so that some special composition is separated, concentrated or purifying.
The open CN101373188A of Chinese invention patent discloses the immue quantitative detection reagent box of CA19-9 (CA19-9) a kind of, this kit comprises the CA19-9 calibration object, be coated with the solid phase carrier of CA19-9 monoclonal antibody, the CA19-9 monoclonal antibody of horseradish peroxidase-labeled, and chemical luminous substrate A liquid, B liquid, wherein said solid phase carrier is microwell plate, plastic bead, plastic tube or magnetic-particle.The CA19-9 monoclonal antibody that is coated with solid phase carrier, the horseradish peroxidase-labeled of CA19-9 monoclonal antibody in this kit consists of the immune response reagent that the immune response step is used.Although this kit can be realized detecting quickly and accurately, but wherein, the preparation process of CA19-9 monoclonal antibody that is coated with the solid phase carrier of CA19-9 monoclonal antibody and horseradish peroxidase-labeled is very loaded down with trivial details, technology stability is bad, limits its detection effect and particularly analyzes a precision and cause cost to increase.
Summary of the invention
Technical matters to be solved by this invention is to overcome the deficiencies in the prior art; the nano magnetic particulate chemistry luminescence assays kit of a kind of sugar antigen CA19-9 is provided; it can prepare with lower cost, and can realize carbohydrate related antigen CA19-9 accurately and high precision quantitative measurement.
The present invention also provides the preparation method of the nano magnetic particulate chemistry luminescence assays kit of a kind of sugar antigen CA19-9 simultaneously, the method process stabilizing, and cost is low, and the precision of gained kit is high.
The nano magnetic particulate chemistry luminescence assays kit of a kind of sugar antigen CA19-9 is characterized in that, this kit comprises:
The first reagent: the solution that contains fluorescein-labeled carbohydrate related antigen CA19-9 antibody;
The second reagent: the solution that contains the carbohydrate related antigen CA19-9 antibody of alkaline phosphatase (ALP) mark;
Magnetic separating agent: the suspending liquid that contains the magnetic particle of coated fluorescein antibody.
Preferably, the carbohydrate related antigen CA19-9 antibody of this alkali phosphatase enzyme mark passes through crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester (Succinimidyl 4-(N-Maleimidomethyl) Cyclohexane-1-Carbo by alkaline phosphatase and carbohydrate related antigen CA19-9 antibody, SMCC) and 2-imino group sulfane hydrochloride (2-Iminothiolane HCl, 2-IT) connect and compose.
Further, in the described magnetic particle reagent, the magnetic particle that is coated with fluorescein antibody passes through the coupling of coupling agent phase chemistry by fluorescein antibody and magnetic particle.
Further, the concentration of the fluorescein-labeled carbohydrate related antigen CA19-9 antibody in described the first reagent is 0.5 ~ 1 μ g/mL, and the pH of described the first reagent is 7-9; The concentration of the carbohydrate related antigen CA19-9 antibody of the alkali phosphatase enzyme mark in described the second reagent is 0.5 ~ 1 μ g/mL, and the pH of described the second reagent is 7-9.
Those skilled in the art should know, and kit of the present invention can further include other and detects required reagent, for example substrate solution.But can buy separately or prepare such as other reagent such as substrate solutions, therefore, although can comprise these reagent in the kit, they be not essential for kit of the present invention.
The another technical scheme that the present invention takes is: the preparation method of the nano magnetic particulate chemistry luminescence assays kit of a kind of sugar antigen CA19-9; it comprises the step for preparing respectively described the first reagent, described the second reagent and magnetic separating agent, and wherein: the preparation process of described the second reagent is as follows:
1. with after room temperature leaves standstill in the carbohydrate related antigen CA19-9 antibody adding crosslinking chemical 2-imino group sulfane hydrochloride solution, add glycine solution, room temperature leaves standstill again, collects the carbohydrate related antigen CA19-9 antibody after activating, and saves backup under 2 ~ 8 ℃ again;
2. the alkaline phosphatase enzyme solutions is added crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester solution, room temperature leaves standstill, and collects the alkaline phosphatase after activating, and saves backup under 2 ~ 8 ℃;
3. with above-mentioned steps 1. the alkaline phosphatase of the carbohydrate related antigen CA19-9 antibody after the gained activation after 2. gained activates with step mix, leave standstill reaction, make the carbohydrate related antigen CA19-9 antibody that generates alkali phosphatase enzyme mark, after reaction finishes, with reactant liquor Supp erdex200 gel-purified post purifying, damping fluid adjustment concentration and the pH value selecting to have proper pH value namely get described the second reagent;
Wherein, the purity of described carbohydrate related antigen CA19-9 antibody, described alkaline phosphatase is all more than or equal to 95wt%, and the specific activity of described alkaline phosphatase surpasses 1000u/mg.
Preferably, step 1. in, get carbohydrate related antigen CA19-9 antibody, add the dissolving of coupling agent 2-IT solution, room temperature leaves standstill 10min ~ 30min, adds glycine solution, room temperature leaves standstill 2 ~ 10min, with G-25 gel-purified post desalination, collect the carbohydrate related antigen CA19-9 antibody after activating, save backup in 2-8 ℃.
Preferably, step 2. in, get concentration more than or equal to the alkaline phosphatase enzyme solutions of 5mg/mL, add and use SMCC solution, room temperature leaves standstill 20 ~ 40min, with G-25 gel column desalination, collects the rear alkaline phosphatase of activation, saves backup in 2-8 ℃.
Preferably, step 3. in, be that 1:1 ~ 1:2 mixes with the alkaline phosphatase of the carbohydrate related antigen CA19-9 antibody of above-mentioned activation and activation by the molecule mol ratio, under 2-8 ℃ of condition, leave standstill 12-24h.
Wherein the damping fluid of proper pH value can be for for example containing the TRIS damping fluid of 0.5% bovine serum albumin(BSA), pH8.0.
Further, the preparation method of described the first reagent is as follows: the pH that preparation contains fluorescein is 9 ~ 10 damping fluid, then the molecular proportion according to fluorescein and carbohydrate related antigen CA19-9 antibody is the ratio of 20 ~ 200:1, be 9 ~ 10 damping fluid with the described pH that contains fluorescein with the pH of carbohydrate related antigen CA19-9 antibody be that 9 ~ 10 damping fluid mixes, behind the mixing, room temperature leaves standstill reaction, then reactant liquor is separated by the G-25 gel column, remove free fluorescein, obtain containing the solution of fluorescein-labeled anti-carbohydrate related antigen CA19-9 antibody, then adjust concentration and pH with the damping fluid with proper pH value, and get final product.Wherein the damping fluid of proper pH value can be for for example containing the TRIS damping fluid of 0.5% bovine serum albumin(BSA), pH8.0.
Further, the preparation method of described magnetic separating agent is as follows: will contain the magnetic particle of carboxyl reactive group and fluorescein antibody in the presence of the coupling agent carbodiimide, room temperature reaction 2 ~ 18 hours, reaction finishes, magnetic separates, remove supernatant, adjust pH and concentration with the damping fluid with proper pH value, namely get described magnetic separating agent.Wherein said magnetic particle has superparamagnetism, and its diameter is 0.5 ~ 2 μ m, on every gram magnetic particle with the content of carboxyl reactive group be not less than 0.4mmol; Described fluorescein antibody is monoclonal antibody or polyclonal antibody, and purity is more than or equal to 90wt%, and dilution is tired greater than 1:100 ten thousand.
Preferably, the above-mentioned damping fluid with proper pH value is the TRIS damping fluid that contains 0.5% bovine serum albumin(BSA), pH8.0.
Fluorescein of the present invention can be known various fluoresceins, and commonly used have for example fluorescein isothiocynate, RB 200, a TRITC etc.
The present invention also provides simultaneously a kind of and has adopted above-mentioned kit to be applied to the detection method that tumor-associated antigen 125 quantitatively detects, and it is characterized in that, may further comprise the steps:
(1) immune response: add sample to be tested stoste in detector tube, add successively the first reagent and the second reagent, mixing carries out the incubation first time under 25 ~ 40 ℃, then add the magnetic separation agent, and mixing carries out the incubation second time under 25～40 ℃;
(2) washing: make magnetic particle sedimentation in magnetic field, remove supernatant, add cleaning fluid, remove magnetic field, concussion makes the abundant suspendible of magnetic particle, and then magnetic separates, and removes supernatant;
(3) add substrate solution and detect luminous intensity: in detector tube, add the chemical luminous substrate of alkaline phosphatase enzymatic, remove magnetic field, fully detect luminous intensity values behind the suspendible.
Further, the time of the incubation first time described in the step (1) can be 10 ~ 20min, is generally 15min; The time of incubation can be 2 ~ 15min for the second time, is generally 5min.
Because the enforcement of above technical scheme, the present invention compared with prior art has following advantage:
1. adopt kit of the present invention can realize accurate, the accurate detection of carbohydrate related antigen CA19-9, its three kinds of reagent all can prepare by stable preparation technology, production cost is low, and because preparation technology's stability, it is little that kit is analyzed differences between batches, and precision improves between the analysis of detection;
2. the preparation method of the solution of the carbohydrate related antigen CA19-9 antibody that contains alkali phosphatase enzyme mark in the kit of the present invention, can be effectively with carbohydrate related antigen CA19-9 antibody and alkaline phosphatase coupling, coupling efficiency is high, further reduces the cost of kit low and guarantee the detection effect of kit;
3. take kit of the present invention to detect, accuracy is good, and precision is high, highly sensitive, sensing range is wide, and sample need not pre-dilution, simple to operate saving time compared with the method that adopts the import reagent box to detect, and detection method of the present invention has significant advantage at cost.
Description of drawings
Fig. 1 is detection calibration product typical curves;
Fig. 2 is that matched curve is estimated in sensitivity;
Fig. 3 is serum sample testing result correlativity (wherein horizontal ordinate x is the kit sample measured value that embodiment 4 is prepared into, and concentration unit is U/mL, and ordinate y is ROCHE company kit sample measured value, and concentration unit is U/mL).
Embodiment
The preparation of embodiment 1 first reagent
(1) material and instrument: with the carbohydrate related antigen CA19-9(CA19-9 of phosphate buffer preservation) monoclonal antibody (purity surpasses 95wt%, and concentration is 2mg/mL); Fluorescein isothiocynate (FITC), the reagent such as sodium carbonate should reach chemical pure; The buying of G-25 gel-purified post is from GE company.
(2) preparation process:
1. use the FITC solution of the carbonate buffer solution preparation 0.5mg/mL of 0.1 ~ 0.2mol/L pH 9.0 ~ 10.0;
2. add step according to CA19-9 antibody and FITC molecular proportion by the ratio of 1:20 in antibody-solutions and 1. joined FITC solution, mix, room temperature left standstill 12h hour, and reaction generates CA19-9 antibody-FITC connector;
3. will separate by the G-25 gel column through step reactant liquor 2., remove unreacted FITC, obtain containing the solution of CA19-9 antibody-FITC connector (being the CA19-9 antibody of FITC mark);
4. with step 3. the gained solution that contains CA19-9 antibody-FITC connector to be diluted to CA19-9 antibody-FITC connector concentration with the TRIS damping fluid of the 0.1mol/L that contains 0.5% bovine serum albumin(BSA) (BSA) pH 8.0 be 0.5 ~ 1 μ g/mL, be the first reagent.
The preparation of embodiment 2 second reagent
(1) material and instrument: with the CA19-9 monoclonal antibody (purity surpasses 95wt%, and concentration is 2mg/mL) of phosphate buffer preservation; The alkaline phosphatase of preserving with phosphate buffer (ALP solution, ALP purity are approximately 99%, and specific activity is about 1500U/mg, and concentration is 10mg/mL); Crosslinking aid S MCC, 2-IT is available from THERMO company, and the chemical reagent such as TRIS should reach chemical pure; G-25 gel-purified post is GE company product.
(2) preparation process:
1. get 1mg CA19-9 antibody, add the coupling agent 2-IT solution 2-4 μ L of 10mg/mL, room temperature leaves standstill 20min, add the glycine solution 10 μ L of 0.1mol/L, room temperature leaves standstill 5min, with G-25 gel column desalination, collect the rear CA19-9 antibody of activation, 2-8 ℃ saves backup;
2. get the ALP solution of 1.5mg, add the SMCC solution 10-20 μ L of 5mg/mL, room temperature leaves standstill 30min, with G-25 gel column desalination, collects the rear ALP of activation, and 2-8 ℃ saves backup;
3. the cancer antigens c A19-9 antibody with above-mentioned activation mixes with the ALP of activation, leaves standstill 12-24h under the 2-8 ℃ of condition, with Supperdex200 gel-purified post purifying conjugate, obtains CA19-9 antibody-ALP connector strong solution, and 2-8 ℃ saves backup;
4. use the TRIS damping fluid of the 0.1mol/L that contains 0.5% bovine serum albumin(BSA) (BSA) pH8.0 to be diluted to 0.5-1 μ g/mL CA19-9 antibody-ALP connector strong solution, finish the preparation of the second reagent.
The preparation of embodiment 3 magnetic separation agents
(1) material and instrument:
The suspending liquid of magnetic particle: magnetic particle content 5wt%, magnetic particle contain the active group of carboxyl (COOH), and every gram (g) magnetic particle (dry weight) carboxyl-content is not less than 0.4 mM (mmol), has superparamagnetism, and diameter is between 0.5-2 μ m.
Anti-FITC mAb: can be polyclonal antibody, also can be monoclonal antibody, and purity is more than the 90wt%, and dilution is tired above 1:100 ten thousand;
MES (MES), carbodiimide (EDC), TRIS and other reagent should reach chemical pure.
(2) preparation process:
1. get the suspending liquid of 100mg magnetic particle, magnetic divides the supernatant of leaving away, and uses 0.05mol/L, and 10mL is resuspended for pH 4.5 ~ 5MES damping fluid;
2. the anti-FITC mAb that adds 2 ~ 4mg, room temperature suspendible 30 ~ 60min;
3. the EDC aqueous solution that adds the freshly prepared 10mg/mL of 0.5 ~ 1mL, room temperature suspendible 2 ~ 12h;
4. magnetic separates, and removes supernatant, uses the TRIS damping fluid of the 0.1mol/L that contains 0.5% bovine serum albumin(BSA) (BSA) pH 8.0 to be resuspended to 1mg/mL, and pH 8.0, are the magnetic separation agent.
The nano magnetic particulate chemistry luminescence assays kit of embodiment 4 sugar antigen CA19-9
This kit comprises:
According to first reagent (concentration is 0.75 μ g/mL) of embodiment 1 method preparation, 50mL;
According to second reagent (concentration is 0.75 μ g/mL) of embodiment 2 methods preparation, 50mL;
Magnetic separation agent 50mL according to the preparation of embodiment 3 methods.
The nano magnetic particulate chemistry luminescence assays kit of embodiment 5 sugar antigen CA19-9
This kit comprises:
According to first reagent (concentration is 0.5 μ g/mL) of embodiment 1 method preparation, 50mL;
According to second reagent (concentration is 0.5 μ g/mL) of embodiment 2 methods preparation, 50mL;
Magnetic separation agent 50mL according to the preparation of embodiment 3 methods.
The nano magnetic particulate chemistry luminescence assays kit of embodiment 6 sugar antigen CA19-9
This kit comprises:
According to first reagent (concentration is 1 μ g/mL) of embodiment 1 method preparation, 50mL;
According to second reagent (concentration is 1 μ g/mL) of embodiment 2 methods preparation, 50mL;
Magnetic separation agent 50mL according to the preparation of embodiment 3 methods.
Embodiment 7 takes the kit of embodiment 4 to carry out the quantitative detection of carbohydrate related antigen CA19-9
(1) detecting step:
1. immune response: in detector tube, add 20 μ L sample to be tested (serum or blood plasma) stostes, then add 50 μ L the first reagent, 50 μ L the second reagent, mixing, incubation 15min under 37 ± 1 ℃ of conditions; Add 50 μ L magnetic separation agents, mixing, incubation 5min under 37 ± 1 ℃ of conditions;
2. washing: make magnetic particle sedimentation in magnetic field, remove supernatant, add the cleaning fluid of 300 μ L, remove magnetic field, concussion makes the abundant suspendible of magnetic particle, and then magnetic separates, and removes supernatant; This step repeats 3 times;
3. add substrate solution and detect luminous intensity: add 100 μ L alkaline phosphatase chemical luminous substrate solution (Beijing Ah APCL-of this Bioisystech Co., Ltd I) in detector tube, concussion makes the abundant suspendible of magnetic particle, detects luminous intensity in 5min.
(2) draw the calibration object typical curve
The calibration object typical curve is referring to Fig. 1.
(3) sensitivity evaluation
Detect " 0 " concentration samples, duplicate detection 20 times, calculate mean value (M) and the standard deviation (SD) of relative luminous intensity (RLU), and calculating M+2SD value, carry out 2 regression fits according to the concentration-RLU between zero-dose calibration object and the adjacent calibration object and draw linear function, the M+2SD value is brought in the above-mentioned equation, obtain corresponding concentration value, be lowest detectable limit.The sensitivity of this method is not more than 2U/mL.Wherein: A point luminous value is respectively referring to table 1:
Table 1
The luminous average X=679 of A point
SD=43.6
X+2SD=766.2
B point luminous value is respectively referring to table 2.
The luminous average X=27042 of B point
Table 2
| CA19-9-STD-B(RLU) |
| 28486 |
| 25597 |
A, B point connect the some matched curve referring to Fig. 2.Sensitivity=0.041U/mL.
(4) precision evaluation
1. precision in analyzing
The kit of embodiment 4 is a collection of, measure respectively the serum of basic, normal, high three kinds of variable concentrations, 10 hole replicate determinations, the result is referring to table 3, and drawing the variation within batch coefficient is 3.69%～6.25%.
Precision test in table 3 is analyzed
| Measure serum-concentration (U/mL) | Measure number of times | CV (%) in analyzing |
| 40 | 10 | 6.25 |
| 80 | 10 | 3.69 |
| 150 | 10 | 4.35 |
2. precision between analyzing
The kit of embodiment 4 is got three batches, and every batch of kit is all measured the serum of basic, normal, high three kinds of variable concentrations, 10 hole replicate determinations.Every part of serum obtains 30 concentration measured values, and referring to table 4, the coefficient of variation between statistical study is 5.65%～7.98%.
Precision test between table 4 is analyzed
| Measure serum-concentration (U/mL) | Measure number of times | CV between analysis (%) |
| 40 | 30 | 7.98 |
| 80 | 30 | 5.65 |
| 150 | 30 | 5.89 |
(5) accuracy estimating
Add different amount CA19-9 standard items in 2 routine pooled serum samples, the serum that forms 3 concentration levels adds sample, and the additive volume is less than 10% of cumulative volume.Detect concentration of specimens, by following formula calculate recovery rate.This method serum matrix recovery is between 85-115%.Data are referring to table 5.
R: the recovery;
V: the volume that adds standard solution;
V
0: the volume of people source sample;
C: people source sample adds the detectable concentration behind the standard solution;
C
0: the detectable concentration of people source sample;
Cs: the concentration of standard solution.
Table 5 accuracy estimating-interpolation recovery experiment data
(6) kit Evaluation on specificity
Check is to choose with carbohydrate related antigen CA19-9 to have the alpha-fetoprotein (AFP) of similar structures, carcinomebryonic antigen (CEA) to be mixed with the sample greater than physiological concentration to the kit specificity, measures with this method.The results are shown in Table 6, this law and AFP, the equal no cross reaction of CEA.
The experiment of table 6 specificity
(7) correlativity evaluation
Chemical luminescence reagent kit with kit and ROCHE company detects simultaneously to 100 parts of human serum samples.Its testing result is referring to accompanying drawing 3, take the change of serum C A19-9 concentration of the survey of the inventive method as horizontal ordinate, result take Perkin Elmer company kit measurement does regretional analysis as ordinate, and dependent equation is: y=-1.2726+0.9962x, related coefficient is: 0.9832.Learn by statistics result and show, this method is good with external kit clinical sample measured value correlativity.
(8) Evaluation of Thermal Stability
Kit is carried out respectively 4 ℃ of 12 months and 37 ℃ of stability experiments of 7 days, the result show kit standard items luminous intensity variation, batch in and the indexs such as betweenrun precision, accuracy all within normal range, the kit term of validity can reach 12 months.
Above-described embodiment only is explanation technical conceive of the present invention and characteristics; its purpose is to allow the personage who is familiar with technique can understand content of the present invention and according to this enforcement; can not limit protection scope of the present invention with this; all equivalences that Spirit Essence is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (10)
1. the nano magnetic particulate chemistry luminescence assays kit of a sugar antigen CA19-9, described kit comprises:
The first reagent: the solution that contains fluorescein-labeled carbohydrate related antigen CA19-9 antibody;
The second reagent: the solution that contains the carbohydrate related antigen CA19-9 antibody of alkali phosphatase enzyme mark;
Magnetic separating agent: the suspending liquid that contains the magnetic particle of coated fluorescein antibody.
2. the nano magnetic particulate chemistry luminescence assays kit of sugar antigen CA19-9 according to claim 1, it is characterized in that: the carbohydrate related antigen CA19-9 antibody of described alkali phosphatase enzyme mark is connected and composed by crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester and 2-imino group sulfane hydrochloride by alkaline phosphatase and carbohydrate related antigen CA19-9 antibody.
3. the nano magnetic particulate chemistry luminescence assays kit of sugar antigen CA19-9 according to claim 1 and 2, it is characterized in that: the concentration of the fluorescein-labeled carbohydrate related antigen CA19-9 antibody in described the first reagent is 0.5 ~ 1 μ g/mL; The pH of described the first reagent is 7-9; The concentration of the carbohydrate related antigen CA19-9 antibody of the alkali phosphatase enzyme mark in described the second reagent is 0.5 ~ 1 μ g/mL, and the pH of described the second reagent is 7-9.
4. the preparation method of the nano magnetic particulate chemistry luminescence assays kit of a sugar antigen CA19-9 as claimed in claim 3; the step that it comprises the suspending liquid of the solution for preparing respectively the described solution that contains fluorescein-labeled carbohydrate related antigen CA19-9 antibody, the described carbohydrate related antigen CA19-9 antibody that contains alkali phosphatase enzyme mark and the described magnetic particle that is coated with fluorescein antibody is characterized in that: the preparation process of the solution of the described carbohydrate related antigen CA19-9 antibody that contains alkali phosphatase enzyme mark is as follows:
1. with after room temperature leaves standstill in the carbohydrate related antigen CA19-9 antibody adding crosslinking chemical 2-imino group sulfane hydrochloride solution, add glycine solution, room temperature leaves standstill again, collects the carbohydrate related antigen CA19-9 antibody after activating, and saves backup under 2 ~ 8 ℃ again;
2. the alkaline phosphatase enzyme solutions is added crosslinking chemical 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester solution, room temperature leaves standstill, and collects the alkaline phosphatase after activating, and saves backup under 2 ~ 8 ℃;
3. with above-mentioned steps 1. the alkaline phosphatase of the carbohydrate related antigen CA19-9 antibody after the gained activation after 2. gained activates with step mix, leave standstill reaction, make the carbohydrate related antigen CA19-9 antibody that generates alkali phosphatase enzyme mark, after reaction finishes, with reactant liquor Supperdex200 gel-purified post purifying, damping fluid adjustment concentration and the pH value selecting to have proper pH value namely get described the second reagent;
Wherein, the purity of described carbohydrate related antigen CA19-9 antibody, described alkaline phosphatase is all more than or equal to 95wt%, and the specific activity of described alkaline phosphatase surpasses 1000u/mg.
5. preparation method according to claim 4, it is characterized in that: step 1. in, get carbohydrate related antigen CA19-9 antibody, add the dissolving of coupling agent 2-IT solution, room temperature leaves standstill 10min ~ 30min, adds glycine solution, room temperature leaves standstill 2 ~ 10min, with G-25 gel-purified post desalination, collect the carbohydrate related antigen CA19-9 antibody after activating, save backup in 2-8 ℃.
6. according to claim 4 or 5 described preparation methods, it is characterized in that: step 2. in, get concentration more than or equal to the alkaline phosphatase enzyme solutions of 5mg/mL, add 4-(N-maleimide ylmethyl) cyclohexane-1-carboxylic acid succinimide ester solution, room temperature leaves standstill 20 ~ 40min, with G-25 gel column desalination, collect the rear alkaline phosphatase of activation, save backup in 2-8 ℃.
7. preparation method according to claim 4, it is characterized in that: the preparation method of described the first reagent is as follows: the pH that preparation contains fluorescein is 9 ~ 10 damping fluid, then the molecular proportion according to fluorescein and anti-carbohydrate related antigen CA19-9 antibody is the ratio of 20 ~ 200:1, be 9 ~ 10 damping fluid with the described pH that contains fluorescein with the pH of anti-carbohydrate related antigen CA19-9 antibody be that 9 ~ 10 damping fluid mixes, behind the mixing, room temperature leaves standstill reaction, then reactant liquor is separated by the G-25 gel column, remove free fluorescein, obtain containing the solution of fluorescein-labeled anti-carbohydrate related antigen CA19-9 antibody, then adjust concentration and pH with the damping fluid with proper pH value, namely get the first reagent.
8. preparation method according to claim 4, it is characterized in that: the preparation method of described magnetic separating agent is as follows: make the magnetic particle that contains the carboxyl reactive group and fluorescein antibody in the presence of the coupling agent carbodiimide, room temperature reaction 2 ~ 18 hours, reaction finishes, magnetic separates, remove supernatant, adjust pH and concentration with the damping fluid with proper pH value, namely get described magnetic separating agent; Wherein said magnetic particle has superparamagnetism, and its diameter is 0.5 ~ 2 μ m, on every gram magnetic particle with the content of carboxyl reactive group more than or equal to 0.4mmol; Described fluorescein antibody is monoclonal antibody or polyclonal antibody, and purity is more than or equal to 90wt%, and dilution is tired greater than 1:100 ten thousand.
9. according to claim 4 or 7 or 8 described preparation methods, it is characterized in that: described damping fluid with proper pH value is the TRIS damping fluid that contains 0.5% bovine serum albumin(BSA), pH8.0.
10. the described kit of each claim is used for the quantitative detection method that detects to carbohydrate related antigen CA19-9 in the employing claim 1 ~ 3, it is characterized in that, may further comprise the steps:
(1) immune response: add sample to be tested stoste in detector tube, add successively the first reagent and the second reagent, mixing carries out the incubation first time under 25 ~ 40 ℃, then add the magnetic separation agent, and mixing carries out the incubation second time under 25 ~ 40 ℃;
(2) washing: make magnetic particle sedimentation in magnetic field, remove supernatant, add cleaning fluid, remove magnetic field, concussion makes the abundant suspendible of magnetic particle, and then magnetic separates, and removes supernatant;
(3) add substrate solution and detect luminous intensity: in detector tube, add the chemical luminous substrate of alkaline phosphatase enzymatic, remove magnetic field, fully detect luminous intensity values behind the suspendible.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550170.8A CN103048453B (en) | 2012-12-18 | 2012-12-18 | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210550170.8A CN103048453B (en) | 2012-12-18 | 2012-12-18 | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103048453A true CN103048453A (en) | 2013-04-17 |
| CN103048453B CN103048453B (en) | 2014-11-26 |
Family
ID=48061167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210550170.8A Active CN103048453B (en) | 2012-12-18 | 2012-12-18 | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103048453B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105092834A (en) * | 2014-05-05 | 2015-11-25 | 江苏泽成生物技术有限公司 | Carbohydrate antigen 19-9 (CA 19-9) quantitative assay kit, preparation method and detection method thereof |
| CN106124776A (en) * | 2016-06-30 | 2016-11-16 | 深圳市亚辉龙生物科技股份有限公司 | CA724 chemiluminescence immune detection reagent kit and preparation method thereof |
| CN106501515A (en) * | 2016-12-07 | 2017-03-15 | 普菲特益斯生物科技（北京）有限公司 | CA215 detection kit and preparation method thereof and using method |
| CN107389946A (en) * | 2017-08-25 | 2017-11-24 | 北京健安生物科技有限公司 | Sugar antigen CA19 9 determines kit and its detection method |
| CN107957495A (en) * | 2017-11-17 | 2018-04-24 | 南通伊仕生物技术股份有限公司 | A kind of CK-MB detection kits and its application method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101324579A (en) * | 2007-06-13 | 2008-12-17 | 清华大学 | Magnetic microparticle chemiluminescence enzyme immune analytic reagent kit for detecting saccharide antigen and its use method |
| CA2760366A1 (en) * | 2009-05-29 | 2010-12-02 | F.Hoffmann-La Roche Ag | Secernin-1 as a marker for cancer |
| CN101937000A (en) * | 2010-08-05 | 2011-01-05 | 北京倍爱康生物技术有限公司 | Magnetic particle separation chemiluminescence immunoassay method of human cystatin C |
| US20120128702A1 (en) * | 2010-11-24 | 2012-05-24 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| US20120141375A1 (en) * | 2002-06-14 | 2012-06-07 | Immunomedics, Inc. | Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer |
-
2012
- 2012-12-18 CN CN201210550170.8A patent/CN103048453B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120141375A1 (en) * | 2002-06-14 | 2012-06-07 | Immunomedics, Inc. | Anti-Mucin Antibodies for Early Detection and Treatment of Pancreatic Cancer |
| CN101324579A (en) * | 2007-06-13 | 2008-12-17 | 清华大学 | Magnetic microparticle chemiluminescence enzyme immune analytic reagent kit for detecting saccharide antigen and its use method |
| CA2760366A1 (en) * | 2009-05-29 | 2010-12-02 | F.Hoffmann-La Roche Ag | Secernin-1 as a marker for cancer |
| CN101937000A (en) * | 2010-08-05 | 2011-01-05 | 北京倍爱康生物技术有限公司 | Magnetic particle separation chemiluminescence immunoassay method of human cystatin C |
| US20120128702A1 (en) * | 2010-11-24 | 2012-05-24 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105092834A (en) * | 2014-05-05 | 2015-11-25 | 江苏泽成生物技术有限公司 | Carbohydrate antigen 19-9 (CA 19-9) quantitative assay kit, preparation method and detection method thereof |
| CN106124776A (en) * | 2016-06-30 | 2016-11-16 | 深圳市亚辉龙生物科技股份有限公司 | CA724 chemiluminescence immune detection reagent kit and preparation method thereof |
| CN106501515A (en) * | 2016-12-07 | 2017-03-15 | 普菲特益斯生物科技（北京）有限公司 | CA215 detection kit and preparation method thereof and using method |
| CN107389946A (en) * | 2017-08-25 | 2017-11-24 | 北京健安生物科技有限公司 | Sugar antigen CA19 9 determines kit and its detection method |
| CN107957495A (en) * | 2017-11-17 | 2018-04-24 | 南通伊仕生物技术股份有限公司 | A kind of CK-MB detection kits and its application method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103048453B (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103063851B (en) | Free triiodothyronine nanometer magnetic particle chemiluminescence assay kit and preparation method thereof and detection method thereof | |
| CN103901203B (en) | Chemical luminescent analysis reagent kid of a kind of Procalcitonin and preparation method thereof and detection method | |
| CN103048452B (en) | Nanometer magnetic particle chemiluminiscence determination kit for antigen CA125 relating to tumor, as well as preparation method and determining method of same | |
| CN102998467B (en) | β human chorionic gonadotrophin magnetic microparticle chemiluminescence immune quantitative detection reagent box and preparation method thereof | |
| CN102507947B (en) | CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads) | |
| CN110726841B (en) | Method for detecting veterinary drug residues based on enzymatic click reaction signal amplification magnetic relaxation time immunosensor | |
| CN103389381B (en) | Human epididymal secretory protein E4 chemiluminescence detection kit and preparation method thereof | |
| CN103364558A (en) | Human tumor marker carcinoembryonic antigen (CEA) magnetic particle chemiluminiscence immunoassay kit and detection method | |
| CN103048453B (en) | Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof | |
| CN103063845A (en) | Nanometer magnetic particle chemiluminiscence kit, preparation method and detection method of hepatitis B virus surface-antibody | |
| CN102901820A (en) | Immunoassay kit and immunodetection method for magnetic particle chemiluminescence of human tumor marker carbohydrate antigen 50 (CA50) | |
| CN104198721B (en) | The preparation of a kind of silica-based magnetic bead bond of GP73 (GP73) antigen and application | |
| CN104034892A (en) | Magnetic particle chemiluminescence immune assay kit of tumor marker AFP (alpha fetal protein) and detection method thereof | |
| CN103076455B (en) | Quantitative detection serum amyloid A protein kit and Synthesis and applications thereof | |
| CN103592445A (en) | Kit for detecting procalcitonin | |
| CN101398431A (en) | Tumor-associated antigen 125 magnetic microparticle chemiluminescence immune assay determination kit and method for making same | |
| CN103344634A (en) | Chemiluminescence immune assay kit and method for magnetic particle of human alpha fetoprotein (AFP) | |
| CN103018445A (en) | Chemiluminiscence immunoassay quantitative detection kit for saccharide antigen 50 magnetic particles and preparation method thereof | |
| CN103048477B (en) | Nanometer magnetic particle chemiluminescence detection kit for triiodothyronine as well as preparation method and detecting method of same | |
| CN103048476A (en) | Thyroxine nanometer magnetic particle chemiluminiscence determinstion kit as well as preparation method and detection method thereof | |
| CN103018465A (en) | Human cystatin C chemiluminescence quantitative detection method | |
| WO2021088730A1 (en) | Free prostate specific antigen measurement kit and preparation method therefor | |
| CN107831314A (en) | A kind of N middle-ends BGP chemiluminescence detection kit and preparation method thereof | |
| CN102608316B (en) | Kit or test strip for detecting quinoxaline compound | |
| CN106324254A (en) | Anti-insulin antibody detection kit and detection method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 building C6 No. 218 Patentee after: Jiangsu Hao Bo biomedical Limited by Share Ltd Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215123 building C6 No. 218 Patentee before: Suzhou Haooubo Biopharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |